---
title: "Artiva Biotherapeutics Q2 FY26 net loss widens to $25.01 million; R&D expenses rise to $21.93 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295139516.md"
description: "Artiva Biotherapeutics reported a widened Q2 FY26 net loss of $25.01 million, driven by increased R&D expenses to $21.93 million. Cash reserves rose to $349.39 million. The FDA granted RMAT designation for AlloNK in refractory rheumatoid arthritis, with Phase 3 trials planned for H2 2026. CEO Fred Aslan highlighted EULAR data supporting AlloNK's potential for deep B-cell depletion and outpatient administration."
datetime: "2026-08-06T20:23:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295139516.md)
  - [en](https://longbridge.com/en/news/295139516.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295139516.md)
generator: "portal-rs"
---

# Artiva Biotherapeutics Q2 FY26 net loss widens to $25.01 million; R&D expenses rise to $21.93 million

-   Artiva Biotherapeutics posted a Q2 net loss of USD 25.01 million, widening from USD 21.25 million a year earlier. \* R&D spending rose to USD 21.93 million from USD 17.86 million, while G&A was little changed at USD 4.97 million. \* Cash, cash equivalents and investments climbed to USD 349.39 million at June 30 from USD 108.01 million at Dec. 31, 2025. \* FDA granted RMAT designation for AlloNK with rituximab in refractory rheumatoid arthritis; Phase 3 start planned in H2 2026 in about 150 patients. \* CEO Fred Aslan said EULAR data reinforced AlloNK’s potential for deep B-cell depletion with tolerability supportive of outpatient administration. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artiva Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608061605PRIMZONEFULLFEED9805015) on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [ARTV.US](https://longbridge.com/en/quote/ARTV.US.md)

## Related News & Research

- [Kreditbanken posts 2026 half-year report release](https://longbridge.com/en/news/296349936.md)
- [Copenhagen Airports publishes H1 2026 interim report](https://longbridge.com/en/news/296606234.md)
- [Public Storage announces R$ 0.41 per unit dividend for Q3 2026](https://longbridge.com/en/news/296635332.md)
- [Corning sets Q3 2026 dividend at R$ 0.25 per unit](https://longbridge.com/en/news/296635714.md)
- [Masoval to present Q2 2026 results in investor briefing](https://longbridge.com/en/news/296509895.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**